Research Nurse Manager
I joined EMERGE in July 2014, and have since integrated into an active, exciting and motivated team of research, clinical and support staff.
I come from the clinical speciality of emergency nursing mostly in Western Australia, and a research/public health background having completed a Masters in Public Health & Tropical Medicine. I also have experience working in areas of conflict with the International Committee of the Red Cross (ICRC) in Africa and the Middle East. I believe research is all about people – the benefit to patients and the belief research instils in staff; we all know why we do research which makes us feel very positive about our roles and the achievements to which we contribute.
A Genome-Wide Association Study Identifies Novel andFunctionally Related Susceptibility Loci for Kawasaki Disease
David Burgner1.*, Sonia Davila2., Willemijn B. Breunis3, Sarah B. Ng2, Yi Li4, Carine Bonnard4, Ling Ling2, Victoria J. Wright5, Anbupalam Thalamuthu4, Miranda Odam1, Chisato Shimizu6, Jane C. Burns6, Michael Levin5, Taco W. Kuijpers3, Martin L. Hibberd2, International Kawasaki Disease Genetics Consortium
PLoS Genetics | www.plosgenetics.org
January 2009 | Volume 5 | Issue 1 | e1000319
Genome-wide association study identifies FCGR2A as a susceptibility locus for Kawasaki disease. Chiea Chuen Khor; Sonia Davila; Willemijn B. Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J. Wright; Rae S.M. Yeung; Dennis E. K. Tan; Kar Seng Sim; Jie Jin Wang; et al.
Chiea Chuen Khor; Sonia Davila; Willemijn B. Breunis; Yi-Ching Lee; Chisato Shimizu; Victoria J. Wright; Rae S.M. Yeung; Dennis E. K. Tan; Kar Seng Sim; Jie Jin Wang; Tien Yin Wong; Junxiong Pang; Paul Mitchell; Rolando Cimaz; Nagib Dahdah; Yiu-Fai Cheung; Guo-Ying Huang; Wanling Yang; In-Sook Park; Jong-Keuk Lee; Jer-Yuarn Wu; Michael Levin; Jane C. Burns; David Burgner; Taco W. Kuijpers; Martin L. Hibberd; Yu-Lung Lau; Jing Zhang; Xiao-Jing Ma; Fang Liu; Lin Wu; Jeong-Jin Yoo; Soo-Jong Hong; Kwi-Joo Kim; Jae-Jung Kim; Young-Mi Park; Young Mi Hong; Sejung Sohn; Gi Young Jang; Kee-Soo Ha; Hyo-Kyoung Nam; Jung-Hye Byeon; Sin Weon Yun; Myung Ki Han; Kyung-Yil Lee; Ja-Young Hwang; Jung-Woo Rhim; Min Seob Song; Hyoung-Doo Lee; Dong Soo Kim; Jae-Moo Lee; Jeng-Sheng Chang; Fuu-Jen Tsai; Chi-Di Liang; Ming-Ren Chen; Hsin Chi; Nan-Chang Chiu; Fu-Yuan Huang; Luan-Yin Chang; Li-Min Huang; Ho-Chang Kuo; Kao-Pin Huang; Meng-Luen Lee; Betau Hwang; Yhu-Chering Huang; Pi-Chang Lee; Miranda Odam; Frank T. Christiansen; Campbell Witt; Paul Goldwater; Nigel Curtis; Pamela Palasanthiran; John Ziegler; Michael Nissen; Clare Nourse; Irene M. Kuipers; Jaap J. Ottenkamp; Judy Geissler; Maarten Biezeveld; Carline Tacke; Luc Filippini; Paul Brogan; Nigel Klein; Vanita Shah; Michael Dillon; Robert Booy; Delane Shingadia; Anu Bose; Thomas Mukasa; Robert Tulloh; Colin Michie; Jane W. Newburger; Annette L. Baker; Anne H. Rowley; Stanford T. Shulman; Wilbert Mason; Masato Takahashi; Marian E. Melish; Adriana H. Tremoulet; Ananth Viswanathan; Elena Rochtchina; John Attia; Rodney Scott; Elizabeth Holliday; Stephen Harrap
Nature Genetics. 2011;43(12):1241-1246
Miranda has also been included as an author in additional publications as part of the International Kawasaki Disease Genetics Consortium.
NMC, AHPRA, RCN
This trial is an open label two-arm randomised trial focused on identifying the best treatment for community acquired sepsis patients. We will be investigating the feasibility of delivering early intravenous fluid resuscitation by comparing 5% human albumin solution (HAS) to balanced crystalloid. Currently, balanced crystalloids are used as routine care and the first line therapy in the international sepsis guidelines, whereas HAS is the second line fluid therapy in septic shock. Although, studies are showing that HAS may have further potential benefits to patients with sepsis.
The purpose of this study is to test a new vaccine, ChAdOx1 nCoV-19, against COVID-19 in healthy volunteers.
The ChAdOx1 nCoV-19 vaccine has been developed in Oxford in an effort to protect healthy people from the pandemic. This study will evaluate the safety of the vaccine and its ability to generate an immune response against the virus.
This is a randomised trial. Participants will be randomly allocated to receive either the ChAdOx1 nCoV-19 vaccine, or a Men ACWY (meningitus vaccine). Volunteers will not be told which vaccine they will receive.
Participants will be asked to return for 6 visits across 12 months to evaluate their health.
Across the UK the trial aims to recruit 10,260 volunteers.
If you are interested in taking part, please click on this link and complete the online questionnaire: https://www.covid19vaccinetrial.co.uk/participate-edinburgh
The purpose of this study is to test a new vaccine against COVID-19 in healthy volunteers.
Assessing the impact of the Minimum Unit Pricing
Assessing the impact of the Minimum Unit Pricing
While considerable efforts have been made to determine the best ways to perform cardiopulmonary resuscitation (CPR) for persons suffering an out-of-hospital cardiac arrest (OHCA), and also to understand what the physical and psychological impact on the victim might be, very little is known about what actually occurs when a lay bystander is suddenly confronted by someone in cardiac arrest.
The First “First Responder”: Understanding bystander actions, experience, and well-being in out-of-hospital cardiac arrest
9 May 2016 | Mia Paderanga
We are very excited to announce that POEM has begun recruitment in the ED. This is a study led by the Royal Berkshire NHS Foundation Trust involving multiple hospitals across the UK. Professor Alasdair Gray is the Principal Investigator for the Royal Infirmary of Edinburgh site.Read more
14 Mar 2016 | Bernadette Gallagher
Have you ever wondered what goes on in the grey matter of Miranda Odam, Research Nurse Manager in EMERGE? Why did she become a nurse? What is her proudest achievement? What wise words does she have to share? You can find out all of the above and more in her Ann Shuttleworth interview featured in the Nursing Life section, Nursing Times 02.03.16, Vol 112: No 9, page 24Read more
15 Apr 2015 | Miranda Odam
We asked a number of colleagues and friends why we do what we do. Their answers are inspiring, challenging and sometimes very funny.Read more